Over 90 percent of people with Huntington’s disease develop chorea. Learn about FDA-approved VMAT2 inhibitors, off-label ...

Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for ...

KILLINGWORTH, Conn. (WTNH) — Neighbors took a stand against Huntington’s Disease on Sunday in Killingworth. The Connecticut ...

Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics ...

Gene-targeting therapies offer unprecedented hope for families facing this inherited brain disorder, but bureaucratic delays ...

ST. LOUIS — Scientists may have reached a breakthrough in the fight against Huntington’s disease, a rare and fatal inherited brain disorder with no cure. For the first time, a gene therapy has been ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. People affected by Huntington’s disease could at last benefit from the ...

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...